Is liver disease a threat to patients with metabolic disorders? (Q36265230)

13 August 2017

1 reference

title

Is liver disease a threat to patients with metabolic disorders? (English)

1 reference

13 August 2017

1 reference

Giulio Marchesini

1

0 references

Elisabetta Bugianesi

series ordinal

3

object named as

Elisabetta Bugianesi

1 reference

13 August 2017

Gabriele Forlani

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

37

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

333-346

1 reference

Narrative review: hepatobiliary disease in type 2 diabetes mellitus

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Clinical features and natural history of nonalcoholic steatosis syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Association of nonalcoholic fatty liver disease with insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Non-alcoholic fatty liver: another feature of the metabolicsyndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Liver fibrosis in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Body fat distribution, relative weight, and liver enzyme levels: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Fatty infiltration of liver in hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Non-alcoholic steatohepatitis in patients cared in metabolic units

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Liver damage in severely obese patients: a clinical-biochemical-morphologic study on 1,000 liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Hepatitis C infection and type 2 diabetes in American-Indian women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Fibrogenic impact of high serum glucose in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

A comparison of fibrosis progression in chronic liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Diabetes increases the risk of acute hepatic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Subacute liver failure in obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Long term prognosis of fatty liver: risk of chronic liver disease and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Nonalcoholic fatty liver disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Obesity and cancer risk: a Danish record-linkage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Excess risk of primary liver cancer in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Diabetes mellitus and the risk of primary liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Role of diabetes mellitus in the etiology of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Mortality from site-specific malignancies in type 2 diabetic patients from Verona

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Obesity and diabetes as a risk factor for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Fasting serum glucose level and cancer risk in Korean men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

A prospective study of obesity and cancer risk (Sweden).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Hepatocellular carcinoma arising in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Challenges and strategies for investigating the genetic complexity of common human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Acute hyperglycemia induces an oxidative stress in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Increased oxidative stress in obesity and its impact on metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Effect of weight reduction on hepatic abnormalities in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Fatty liver--an additional and treatable feature of the insulin resistance syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Selected major risk factors and global and regional burden of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Type 2 Diabetes and the Naaman Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Estimates of global and regional potential health gains from reducing multiple major risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Prospective Study of Serum -Glutamyltransferase and Risk of NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Metabolic syndrome and ALT: a community study in adult Koreans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Attributable risks for hepatocellular carcinoma in Northern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890510011445

10.1080/07853890510011445

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference